中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2015年
4期
247-252
,共6页
杨晓晨%胡震%吴炅%柳光宇%沈镇宙%邵志敏
楊曉晨%鬍震%吳炅%柳光宇%瀋鎮宙%邵誌敏
양효신%호진%오경%류광우%침진주%소지민
BRCA1%BRCA2%乳腺癌%外显率
BRCA1%BRCA2%乳腺癌%外顯率
BRCA1%BRCA2%유선암%외현솔
BRCA1%BRCA2%Breast cancer%Penetrance
背景与目的:BRCA1和BRCA2基因突变携带者终生患乳腺癌和卵巢癌的风险显著增高。通过遗传咨询,突变携带者可采取适当的措施来降低相应肿瘤的发生风险。目前,相关的报道几乎均为白种人,尚缺乏中国人群的资料。该研究旨在探索中国汉族人群中BRCA1和BRCA2基因突变携带者患乳腺癌的风险。方法:回顾20个经基因检测证实携带BRCA1或BRCA2致病性基因突变的汉族乳腺癌高风险家系。利用Kaplan-Meier生存分析法对女性BRCA1/2基因突变携带者单侧乳腺癌及对侧乳腺癌的累积发病风险进行估算。结果:BRCA1和BRCA2基因突变携带者70岁时单侧乳腺癌的累积发病风险(外显率)分别为67.2%(sx 0.100)和76.8%(sx 0.079)。与BRCA1不同的是,BRCA2基因突变携带者70岁后乳腺癌累积发病率继续增加,到80岁时达93.1%。BRCA1/2基因突变携带者对侧乳腺癌10年和20年的累积发病率分别为19.4%(sx 0.089)和50.3%(sx 0.155)。结论:中国汉族人群中BRCA1和BRCA2基因突变携带者具有很高的乳腺癌发病风险。因而对中国高风险人群进行BRCA1/2基因突变检测具有重要临床意义。
揹景與目的:BRCA1和BRCA2基因突變攜帶者終生患乳腺癌和卵巢癌的風險顯著增高。通過遺傳咨詢,突變攜帶者可採取適噹的措施來降低相應腫瘤的髮生風險。目前,相關的報道幾乎均為白種人,尚缺乏中國人群的資料。該研究旨在探索中國漢族人群中BRCA1和BRCA2基因突變攜帶者患乳腺癌的風險。方法:迴顧20箇經基因檢測證實攜帶BRCA1或BRCA2緻病性基因突變的漢族乳腺癌高風險傢繫。利用Kaplan-Meier生存分析法對女性BRCA1/2基因突變攜帶者單側乳腺癌及對側乳腺癌的纍積髮病風險進行估算。結果:BRCA1和BRCA2基因突變攜帶者70歲時單側乳腺癌的纍積髮病風險(外顯率)分彆為67.2%(sx 0.100)和76.8%(sx 0.079)。與BRCA1不同的是,BRCA2基因突變攜帶者70歲後乳腺癌纍積髮病率繼續增加,到80歲時達93.1%。BRCA1/2基因突變攜帶者對側乳腺癌10年和20年的纍積髮病率分彆為19.4%(sx 0.089)和50.3%(sx 0.155)。結論:中國漢族人群中BRCA1和BRCA2基因突變攜帶者具有很高的乳腺癌髮病風險。因而對中國高風險人群進行BRCA1/2基因突變檢測具有重要臨床意義。
배경여목적:BRCA1화BRCA2기인돌변휴대자종생환유선암화란소암적풍험현저증고。통과유전자순,돌변휴대자가채취괄당적조시래강저상응종류적발생풍험。목전,상관적보도궤호균위백충인,상결핍중국인군적자료。해연구지재탐색중국한족인군중BRCA1화BRCA2기인돌변휴대자환유선암적풍험。방법:회고20개경기인검측증실휴대BRCA1혹BRCA2치병성기인돌변적한족유선암고풍험가계。이용Kaplan-Meier생존분석법대녀성BRCA1/2기인돌변휴대자단측유선암급대측유선암적루적발병풍험진행고산。결과:BRCA1화BRCA2기인돌변휴대자70세시단측유선암적루적발병풍험(외현솔)분별위67.2%(sx 0.100)화76.8%(sx 0.079)。여BRCA1불동적시,BRCA2기인돌변휴대자70세후유선암루적발병솔계속증가,도80세시체93.1%。BRCA1/2기인돌변휴대자대측유선암10년화20년적루적발병솔분별위19.4%(sx 0.089)화50.3%(sx 0.155)。결론:중국한족인군중BRCA1화BRCA2기인돌변휴대자구유흔고적유선암발병풍험。인이대중국고풍험인군진행BRCA1/2기인돌변검측구유중요림상의의。
Background and purpose: BRCA1 and BRCA2 mutation carriers have a high lifetime risk of developing breast and ovarian cancer. Through genetic counseling, mutation carriers can take the appropriate measures to reduce such cancer risk. At present, almost all related studies were conducted in Caucasian, while, the studies in Chinese population were rare. This study aimed to investigate the risk of breast cancer in BRCA1 and BRCA2 mutation carriers in Chinese Han population. Methods:Twenty unrelated families with BRCA1 or BRCA2 mutations were re-viewed. Kaplan-Meier analyses were used to estimate the cumulative risks of unilateral breast cancer and contralateral breast cancer for female BRCA1 and BRCA2 mutation carriers. Results:Breast cancer risk to 70 years (penetrance) was 67.2%(sx 0.100) for BRCA1 and 76.8%(sx 0.079) for BRCA2, respectively. Different from BRCA1 mutation carriers, the cumulative incidence of breast cancer in BRCA2 mutation carriers remained increasing after 70 years, reaching 93.1%at age 80. The 10-and 20-year risk for contralateral breast cancer was 19.4%(sx 0.089) and 50.3%(sx 0.155) for BRCA1/2 mutation carriers. Conclusion:BRCA1 and BRCA2 mutation carriers in Chinese Han population have a high risk of developing breast cancer. Thus, it has great clinical signiifcance to test mutations in BRCA1/2 genes in Chinese high-risk population.